A
Ayalew Tefferi
Researcher at Mayo Clinic
Publications - 1234
Citations - 72100
Ayalew Tefferi is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Myelofibrosis & Essential thrombocythemia. The author has an hindex of 125, co-authored 1119 publications receiving 64409 citations. Previous affiliations of Ayalew Tefferi include Celgene & Wrocław Medical University.
Papers
More filters
Journal ArticleDOI
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L. Levine,Ross L. Levine,Martha Wadleigh,Jan Cools,Benjamin L. Ebert,Benjamin L. Ebert,Gerlinde Wernig,Brian J. P. Huntly,Titus J. Boggon,Iwona Wlodarska,Jennifer J. Clark,Sandra A. Moore,Jennifer Adelsperger,Sumin Koo,Jeffrey C. Lee,Stacey Gabriel,Thomas Mercher,Alan D. D'Andrea,Stefan Fröhling,Konstanze Döhner,Peter Marynen,Peter Vandenberghe,Ruben A. Mesa,Ayalew Tefferi,James D. Griffin,Michael J. Eck,William R. Sellers,William R. Sellers,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Todd R. Golub,Stephanie J. Lee,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland +36 more
TL;DR: High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.
Journal ArticleDOI
A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
Jan Cools,Jan Cools,Daniel J. DeAngelo,Jason Gotlib,Elizabeth H. Stover,Robert D. Legare,Robert D. Legare,J. E. Cortes,Jeffrey L. Kutok,Jennifer J. Clark,Ilene Galinsky,James D. Griffin,Nicholas C.P. Cross,Ayalew Tefferi,James M. Malone,Rafeul Alam,Stanley L. Schrier,Janet L. Schmid,Michal G. Rose,Peter Vandenberghe,Gregor Verhoef,Marc Boogaerts,Iwona Wlodarska,Hagop M. Kantarjian,Peter Marynen,Steven Coutre,Richard Stone,D. Gary Gilliland +27 more
TL;DR: The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRalpha is the target of imatinib, and data indicate that the deletion of genetic material may result in gain-of-function fusion proteins.
Journal ArticleDOI
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes,Brigitte Dupriez,Arturo Pereira,Francesco Passamonti,John T. Reilly,Enrica Morra,Alessandro M. Vannucchi,Ruben A. Mesa,Jean Loup Demory,Giovanni Barosi,Elisa Rumi,Ayalew Tefferi +11 more
TL;DR: In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups.
Journal ArticleDOI
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Srdan Verstovsek,Hagop M. Kantarjian,Ruben A. Mesa,Animesh Pardanani,Jorge Cortes-Franco,Deborah A. Thomas,Zeev Estrov,Jordan S. Fridman,Edward C Bradley,Susan Erickson-Viitanen,Kris Vaddi,Richard S. Levy,Ayalew Tefferi +12 more
TL;DR: INCB018424 was associated with marked and durable clinical benefits in patients with myelofibrosis for whom no approved therapies existed, and clinical benefits were associated with a marked diminution of levels of circulating inflammatory cytokines that are commonly elevated in myel ofibrosis.
Journal ArticleDOI
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Animesh Pardanani,Ross L. Levine,Terra L. Lasho,Yana Pikman,Ruben A. Mesa,Martha Wadleigh,David P. Steensma,Michelle A. Elliott,Alexandra P. Wolanskyj,William J. Hogan,Rebecca F. McClure,Mark R. Litzow,D. Gary Gilliland,Ayalew Tefferi +13 more
TL;DR: In this paper, a gain-of-function MPL mutation, MPLW515L, was described in patients with JAK2V617F-negative myelofibrosis with myeloid metaplasia (MMM).